As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class
This article was originally published in The Pink Sheet Daily
Executive Summary
In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.
You may also be interested in...
Pain Market Draws New NDA Submissions
Pharma giant J&J and specialty drug company Javelin Pharmaceuticals are both seeking NDAs for new formulations of already approved pain medications.
Pain Market Draws New NDA Submissions
Pharma giant J&J and specialty drug company Javelin Pharmaceuticals are both seeking NDAs for new formulations of already approved pain medications.
Reopening Of Public Comment Period For Opioid Class REMS Confirms Long Road Ahead
FDA is reopening the public comment period for the class-wide opioid Risk Evaluation and Mitigation Strategy until Oct. 19, 2010.